1
AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON JULY 2, 2001
REGISTRATION NO. -
================================================================================
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
----------------------
FORM S-3
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
----------------------
NEOTHERAPEUTICS, INC.
(Exact Name of Registrant as Specified in Its Charter)
----------------------
DELAWARE 93-079187
(State or Other Jurisdiction of (I.R.S. Employer
Incorporation or Organization) Identification No.)
----------------------
157 TECHNOLOGY DRIVE
IRVINE, CALIFORNIA 92618
(949) 788-6700
(Address, Including Zip Code and Telephone Number, Including Area Code, of
Registrant's Principal Executive Offices)
----------------------
ALVIN J. GLASKY, PH.D.
CHIEF EXECUTIVE OFFICER
157 TECHNOLOGY DRIVE
IRVINE, CALIFORNIA 92618
(949) 788-6700
(Name, Address, Including Zip Code and Telephone Number, Including Area Code,
of Agent for Service)
----------------------
Copies to:
----------------------
Alan W. Pettis, Esq.
Latham & Watkins
650 Town Center Drive, Twentieth Floor
Costa Mesa, California 92626
(714) 540-1235
APPROXIMATE DATE OF COMMENCEMENT OF PROPOSED SALE TO THE PUBLIC: As soon
as practical after this Registration Statement becomes effective.
If the only securities being registered on this form are being offered
pursuant to dividend or interest reinvestment plans, please check the following
box. [ ]
If any of the securities being registered on this form are to be offered
on a delayed or continuous basis pursuant to Rule 415 under the Securities Act
of 1933, other than securities offered only in connection with dividend or
interest reinvestment plans, check the following box. [X]
If this form is filed to register additional securities for an offering
pursuant to Rule 462(b) under the Securities Act, please check the following box
and list the Securities Act registration statement number of the earlier
effective registration statement of the same offering. [ ]
If this Form is a post-effective amendment filed pursuant to Rule 462(c)
under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement
for the same offering. [ ]
If delivery of the prospectus is expected to be made pursuant to Rule
434, please check the following box. [ ]
CALCULATION OF REGISTRATION FEE
==========================================================================================================
AMOUNT TO PROPOSED MAXIMUM PROPOSED MAXIMUM AMOUNT OF
TITLE OF SECURITIES BE OFFERING PRICE AGGREGATE REGISTRATION
TO BE REGISTERED REGISTERED(1) PER SHARE OFFERING PRICE FEE
------------------- ------------- ---------------- ---------------- ------------
Common Stock issuable upon
exercise of warrants 30,000 shares $6.10(2) $183,000.00 $45.75
Common Stock issuable upon
conversion of preferred
stock 1,374,046 $4.17(3) $5,729,771.82 $1,432.44
Total 1,404,046 $5,912,771.82 $1,478.19
==========================================================================================================
(1) In the event of a stock split, stock dividend, or similar transaction
involving the Company's common stock, in order to prevent dilution, the
number of shares registered shall automatically be increased to cover
the additional shares in accordance with Rule 416(a) under the
Securities Act.
(2) The exercise price of the warrants, used for the purpose of calculating
the amount of the registration fee in accordance with Rule 457(g) under
the Securities Act.
(3) Estimated solely for the purpose of calculating the amount of the
registration fee in accordance with Rule 457(c) under the Securities Act
of 1933 based on the average of the high and low sales prices of the
Registrant's common stock on the Nasdaq National Market on June 28, 2001
The Registrant hereby amends this Registration Statement on such date or
dates as may be necessary to delay its effective date until the Registrant shall
file a further amendment which specifically states that this Registration
Statement shall thereafter become effective in accordance with Section 8(a) of
the Securities Act of 1933 or until the Registration Statement shall become
effective on such date as the Securities and Exchange Commission, acting
pursuant to said Section 8(a), may determine.
================================================================================
2
SUBJECT TO COMPLETION, DATED JULY 2, 2001
INFORMATION CONTAINED HEREIN IS SUBJECT TO COMPLETION OR AMENDMENT. A
REGISTRATION STATEMENT RELATING TO THESE SECURITIES HAS BEEN FILED WITH THE
SECURITIES AND EXCHANGE COMMISSION. THESE SECURITIES MAY NOT BE SOLD NOR MAY
OFFERS TO BUY BE ACCEPTED PRIOR TO THE TIME THE REGISTRATION STATEMENT BECOMES
EFFECTIVE. THIS PROSPECTUS SHALL NOT CONSTITUTE AN OFFER TO SELL OR THE
SOLICITATION OF AN OFFER TO BUY NOR SHALL THERE BE ANY SALE OF THESE SECURITIES
IN ANY STATE IN WHICH SUCH OFFER, SOLICITATION OR SALE WOULD BE UNLAWFUL PRIOR
TO REGISTRATION OR QUALIFICATION UNDER THE SECURITIES LAWS OF ANY SUCH STATE.
PROSPECTUS
UP TO 1,404,046 SHARES OF
NEOTHERAPEUTICS, INC.
COMMON STOCK
Our common stock is traded on the Nasdaq National Market under the
symbol "NEOT." On June 28, 2001, the closing price of our common stock was
$4.09.
This prospectus relates to the sale of up to 1,404,046 shares of our
common stock by Societe Generale, a bank organized under the laws of France. We
will not receive any of the proceeds from the sale of these shares.
INVESTING IN OUR COMMON STOCK INVOLVES A HIGH DEGREE OF RISK. SEE "RISK
FACTORS" BEGINNING ON PAGE 1
----------------------
Neither the Securities and Exchange Commission nor any state securities
commission has approved or disapproved of these securities or passed upon the
accuracy or adequacy of the prospectus. Any representation to the contrary is a
criminal offense.
----------------------
The date of this prospectus is July __, 2001
3
NO DEALER, SALESPERSON OR OTHER INDIVIDUAL HAS BEEN AUTHORIZED TO GIVE ANY
INFORMATION OR TO MAKE ANY REPRESENTATIONS OTHER THAN CONTAINED OR INCORPORATED
BY REFERENCE IN THIS PROSPECTUS, AND IF GIVEN OR MADE, SUCH INFORMATION OR
REPRESENTATIONS MUST NOT BE RELIED UPON AS HAVING BEEN AUTHORIZED BY THE COMPANY
OR ANY UNDERWRITER. THIS PROSPECTUS DOES NOT CONSTITUTE AN OFFER OR SOLICITATION
BY ANYONE IN ANY JURISDICTION IN WHICH SUCH OFFER OR SOLICITATION IS NOT
AUTHORIZED OR IN WHICH THE PERSON MAKING SUCH OFFER IS NOT QUALIFIED TO DO SO OR
TO ANYONE TO WHOM IT IS UNLAWFUL TO MAKE SUCH OFFER OR SOLICITATION. NEITHER THE
DELIVERY OF THIS PROSPECTUS NOR ANY SALE MADE HEREUNDER SHALL, UNDER ANY
CIRCUMSTANCE, CREATE ANY IMPLICATION THAT THERE HAS NOT BEEN ANY CHANGE IN THE
AFFAIRS OF THE COMPANY SINCE THE DATE HEREOF.
TABLE OF CONTENTS
PAGE
----
ABOUT NEOTHERAPEUTICS......................................................................1
RISK FACTORS...............................................................................1
FORWARD-LOOKING STATEMENTS.................................................................9
ISSUANCE OF COMMON STOCK TO THE SELLING STOCKHOLDERS.......................................9
USE OF PROCEEDS...........................................................................10
SELLING STOCKHOLDERS......................................................................10
PLAN OF DISTRIBUTION......................................................................11
VALIDITY OF COMMON STOCK..................................................................12
EXPERTS...................................................................................12
LIMITATION ON LIABILITY AND DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION FOR
SECURITIES ACT LIABILITIES........................................................12
WHERE YOU CAN FIND MORE INFORMATION.......................................................13
4
ABOUT NEOTHERAPEUTICS
NeoTherapeutics, Inc. is a development stage biopharmaceutical company
engaged in the discovery and development of novel therapeutic drugs intended to
treat neurological diseases and conditions, such as memory deficits associated
with Alzheimer's disease and aging, spinal cord injuries, Parkinson's disease,
other degenerative diseases that affect the nervous system and psychiatric
diseases. We have also recently become engaged in research involving functional
genomics, or the study of how genes function in the body, and the development of
drugs for the treatment of cancer. Our lead product candidate, Neotrofin(TM)
(also known as AIT-082 or leteprinim potassium), and other compounds under
development, are based on our patented technology. This technology uses small
synthetic molecules to create non-toxic compounds, intended to be administered
orally or by injection, that are capable of passing through the blood-brain
barrier, which is a layer of cells which prevents some molecules that may be
harmful from entering the brain, to rapidly act upon specific target cells in
specific locations in the central nervous system, including the brain. Animal
and laboratory tests have shown that Neotrofin(TM) appears to selectively
increase the production of certain neurotrophic factors, a type of large protein
involved in nerve cell proliferation, differential and survival, in selected
areas of the brain and in the spinal cord. These neurotrophic factors regulate
nerve cell growth and function. Our technology has been developed to capitalize
on the beneficial effects of these proteins, which have been widely acknowledged
to be closely involved in the early formation and differentiation of the central
nervous system. We believe that Neotrofin(TM) could have therapeutic and
regenerative effects. We have observed no serious negative side effects in
patients receiving Neotrofin(TM) in our clinical trials, however, patients have
reported experiencing fatigue, headache, nausea, confusion and depression at
rates consistent with those normally seen in the elderly Alzheimer's disease
test population. NeoGene Technologies, Inc., a subsidiary of NeoTherapeutics,
Inc., is engaged in functional genomics research. On November 16, 2000, we
formed another subsidiary, NeoOncoRx, Inc., for the purpose of in-licensing
anti-cancer compounds which are in the clinical trial stages of development.
We currently have no marketable products, and do not expect to have any
products commercially available for at least two years, if at all. We have
incurred substantial losses since our inception, and expect our losses to
continue for at least the next several years. The pharmaceutical marketplace in
which we operate is highly competitive, and includes many large,
well-established companies pursuing treatments for Alzheimer's disease and some
of the other applications we are pursuing. See "Risk Factors" below.
This prospectus relates to the sale of up to 1,397,088 shares of our
common stock by Societe Generale, a bank organized under the laws of France,
which may be issued by us upon conversion of convertible preferred stock and
exercise of warrants issued to Societe Generale in a private placement
transaction pursuant to a Securities Purchase Agreement dated December 18, 2000.
See "Issuance of Common Stock to Selling Stockholders" on page 9.
We were incorporated in Colorado in December 1987 and reincorporated in
Delaware in June 1997. Our executive offices are located at 157 Technology
Drive, Irvine, California 92618. Our telephone number is (949) 788-6700. Our web
site address is www.neotherapeutics.com. Information contained in our web site
does not constitute part of this prospectus.
RISK FACTORS
Your investment in our common stock involves a high degree of risk. You
should consider the risks described below and the other information contained in
this prospectus carefully before deciding to invest in our common stock. If any
of the following risks actually occur, our business, financial condition and
operating results would be harmed. As a result, the trading price of our common
stock could decline, and you could lose a part or all of your investment.
OUR LOSSES WILL CONTINUE TO INCREASE AS WE EXPAND OUR DEVELOPMENT EFFORTS, AND
OUR EFFORTS MAY NEVER RESULT IN PROFITABILITY.
Our cumulative losses during the period from our inception in 1987
through March 31, 2001 were approximately $101.7 million, almost all of which
consisted of research and development and general and administrative expenses.
We lost approximately $11.6 million in 1998, $26.0 million in 1999,
approximately $46.4
1
5
million in 2000 and approximately $5.5 million in the three months ended March
31, 2001. We expect our losses to decrease in the year 2001 as compared to the
year 2000 due to anticipated savings from our transition to managing our
clinical trials ourselves rather than contracting with third parties for this
function. However, we expect our losses to increase in the future as we expand
our clinical trials and increase our research and development activities. We
currently do not sell any products and we may never achieve significant revenues
or become profitable. Even if we eventually generate revenues from sales, we
nevertheless expect to incur significant operating losses over the next several
years.
OUR POTENTIAL DRUG PRODUCTS ARE IN AN EARLY STAGE OF CLINICAL AND PRECLINICAL
DEVELOPMENT AND MAY NOT PROVE SAFE OR EFFECTIVE ENOUGH TO OBTAIN REGULATORY
APPROVAL TO SELL ANY OF THEM.
We currently are testing our first potential drug product,
Neotrofin(TM), in human clinical trials. We are currently conducting three
trials of Neotrofin(TM) for Alzheimer's disease, spinal cord injury and
Parkinson's disease, and we expect to complete these trials before the end of
the first quarter of 2002. We expect that we will need to complete additional
trials before we will be able to apply for regulatory approval to sell
Neotrofin(TM). Our other proposed products are in preclinical development. We
cannot be certain that any of our potential or proposed products will prove to
be safe or effective in treating disorders of the central nervous system or any
other diseases. All of our potential drugs will require additional research and
development, testing and regulatory clearance before we can sell them. We cannot
be certain that we will receive regulatory approval to sell any of our potential
drugs. We do not expect to have any products commercially available for at least
two years, if at all.
IF WE ARE UNABLE TO OBTAIN SUBSTANTIAL ADDITIONAL FUNDING ON ACCEPTABLE TERMS,
WE MAY HAVE TO DELAY OR ELIMINATE ONE OR MORE OF OUR DEVELOPMENT PROGRAMS.
We currently are spending cash at a rate in excess of approximately $2.3
million per month, and we expect this rate of spending to continue for at least
the following 12 months. On April 17, 2001, we entered into an agreement with
two investors which provided for a sale of common stock by us to the investors
for proceeds of $6.0 million, obligated the investors to buy from us convertible
debentures, or debt obligations convertible into shares of our common stock, in
two blocks, one of $10 million in May 2001 and a second one of $8 million in
November 2001. The agreement provided for a penalty payment by us of up to $1
million if we declined to sell the convertible debentures (see Note 15 to the
audited financial statements in our Amendment No. 1 on Form 10-K/A our Annual
Report on Form 10-K filed on April 25, 2001). In May 2001 we declined to sell
the first $10 million block of convertible debentures, and instead agreed to
sell common stock and warrants to the investors for proceeds of $5.95 million
and to reduce the penalty payment to $405,000. We believe that, together with
periodic sales of common stock such as the four sales totaling approximately
$20.5 million in February through May 2001, and assuming that the holders of our
Class B Warrants continue to exercise our Class B Warrants in response to our
call notices, our cash and capital resources will satisfy our current funding
requirements for at least the next twelve months. If the market price of our
common stock is less than $2.00 per share, we may not be able to use our Class B
Warrants as a financing source. As of June 21, 2001, Class B Warrants have been
exercised for 586,400 shares and gross proceeds of approximately $5.1 million.
We have not issued any call notices under our Class B Warrants since November
2000. Should we not be able to continue periodic sales of our common stock or
utilize our Class B Warrants, we may have to seek additional funding. We may not
be able to obtain additional funds on acceptable terms or at all. If adequate
funds are not available, we will have to delay or eliminate one or more of our
development programs.
We expect that we will need substantial additional funds to complete
development and clinical trials of Neotrofin(TM), our lead drug candidate,
before we will be able to submit it to the FDA for approval for commercial sale,
and to support the continued development of our other potential products. Since
we currently have no products available for commercial sale and essentially no
revenues, we must use capital to fund our operating expenses. Our operating
expenses, and consequently our capital requirements, will depend on many
factors, including:
- continued scientific progress in research and development to
identify and develop additional product candidates beyond our
lead compound Neotrofin(TM);
- the costs and progress of preclinical and clinical testing of
Neotrofin(TM) and additional drug candidates;
- the cost involved in filing, prosecuting and enforcing patent
claims; and
2
6
- the time and cost involved in obtaining regulatory approvals for
our potential products.
In addition, if we are successful in obtaining regulatory approval of one or
more of our potential products, we will require additional capital to cover
costs associated with commercializing our products.
We expect to seek additional funding through public or private
financings or collaborative or other arrangements with third parties. We may not
obtain additional funds on acceptable terms, if at all. If adequate funds are
not available, we will have to delay or eliminate one or more of our development
programs.
COMPETITION FOR PATIENTS IN CONDUCTING CLINICAL TRIALS AND EXTENSIVE REGULATIONS
GOVERNING THE CONDUCT OF CLINICAL TRIALS MAY PREVENT OR DELAY APPROVAL OF A DRUG
CANDIDATE AND STRAIN OUR LIMITED FINANCIAL RESOURCES.
Many pharmaceutical companies are conducting clinical trials in patients
with Alzheimer's disease. As a result, we must compete with them for clinical
sites, physicians and the limited number of patients with Alzheimer's disease
who fulfill the stringent requirements for participation in clinical trials. Due
to a lack of available information about the condition of Alzheimer's disease
sufferers in the United States, we cannot be certain how many of the over 4
million patients with Alzheimer's disease in the United States would meet the
requirements for participating in our clinical trials. In addition, due to the
confidential nature of clinical trials, we cannot be certain how many of these
patients may be enrolled in competing studies and consequently not available to
us. This competition may increase costs of our clinical trials and delay the
introduction of our potential products.
ANY FAILURE TO COMPLY WITH EXTENSIVE GOVERNMENTAL REGULATION COULD PREVENT OR
DELAY PRODUCT APPROVAL OR CAUSE GOVERNMENTAL AUTHORITIES TO DISALLOW OUR
PRODUCTS AFTER APPROVAL AND SUBJECT US TO CRIMINAL OR CIVIL LIABILITIES.
The U.S. Food and Drug Administration, or FDA, and comparable agencies
in foreign countries impose many requirements on the introduction of new drugs
through lengthy and detailed clinical testing procedures, and other costly and
time consuming compliance procedures. These requirements apply to every stage of
the clinical trial process and make it difficult to estimate when Neotrofin(TM)
or any other potential product will be available commercially, if at all.
Our proprietary compounds will require substantial clinical trials and
FDA review as new drugs. Even if we successfully enroll patients in our clinical
trials, patients may not respond to our potential drug products. We think it is
prudent to expect setbacks. While we believe that we are currently in compliance
with applicable FDA regulations, if we fail to comply with the regulations
applicable to our clinical testing, the FDA may delay, suspend or cancel our
clinical trials, or the FDA might not accept the test results. The FDA, or any
comparable regulatory agency in another country, may suspend clinical trials at
any time if it concludes that the trials expose subjects participating in such
trials to unacceptable health risks. Further, human clinical testing may not
show any current or future product candidate to be safe and effective to the
satisfaction of the FDA or comparable regulatory agencies or the data derived
therefrom may be unsuitable for submission to the FDA or other regulatory
agencies.
We cannot predict with certainty when we might submit any of our
proposed products currently under development for the regulatory approval
required in order to commercially sell the products. Once we submit a proposed
product for commercial sale approval, the FDA or other regulatory agencies may
not issue their approvals on a timely basis, if at all. If we are delayed or
fail to obtain these approvals, our business may be damaged. If we fail to
comply with regulatory requirements, either prior to seeking approval or in
marketing our products after approval, we could be subject to regulatory or
judicial enforcement actions. These actions could result in:
- product recalls or seizures;
- injunctions;
- civil penalties;
- criminal prosecution;
- refusals to approve new products and withdrawal of existing
approvals; and
- enhanced exposure to product liabilities.
3
7
THE LOSS OF KEY RESEARCHERS OR MANAGERS COULD HINDER OUR DRUG DEVELOPMENT
PROCESS SIGNIFICANTLY AND MIGHT CAUSE OUR BUSINESS TO FAIL.
Our success depends upon the contributions of our key management and
scientific personnel, especially Dr. Alvin Glasky, our Chief Executive Officer
and Chief Scientific Officer. Dr. Glasky has led our research and business
developments since founding our business in 1987 and is the inventor on several
of our patents. Our loss of the services of Dr. Glasky or any other key
personnel could delay or preclude us from achieving our business objectives.
Although we currently have key-man life insurance on Dr. Glasky in the face
amount of $2 million, we believe that the loss of Dr. Glasky's services would
damage our research and development efforts substantially. Dr. Glasky is party
to an employment agreement with us which provides for a three year term expiring
December 31, 2003, with automatic renewals thereafter unless we or Dr. Glasky
gives notice of intent not to renew at lease 90 days in advance of the renewal
date.
In addition to Dr. Glasky, the loss of Dr. Luigi Lenaz, our Vice
President, Oncology Division and President of our subsidiary NeoOncoRx, Inc.,
would damage the development of our anti-cancer business substantially, and the
loss of the services of Dr. Olivier Civelli, consultant to our subsidiary
NeoGene, Inc., would harm the development of our functional genomics business
substantially. We also will need substantial additional expertise in finance and
marketing and other areas in order to achieve our business objectives.
Competition for qualified personnel among pharmaceutical companies is intense,
and the loss of key personnel, or the inability to attract and retain the
additional skilled personnel required for the expansion of our business, could
damage our business.
IF WE CANNOT PROTECT OR ENFORCE OUR INTELLECTUAL PROPERTY RIGHTS ADEQUATELY, THE
VALUE OF OUR RESEARCH COULD DECLINE AS OUR COMPETITORS APPROPRIATE PORTIONS OF
OUR RESEARCH.
We actively pursue patent protection for our proprietary products and
technologies. We hold four U.S. patents and currently have sixteen U.S. patent
applications pending, including three which have been allowed. Our issued
patents expire between 2009 and 2014. In addition, we have numerous foreign
patents issued and patent applications pending corresponding to our U.S.
patents. However, our patents may not protect us against our competitors. We may
have to file suit to protect our patents or to defend our use of our patents
against infringement claims brought by others. Because we have limited cash
resources, we may not be able to afford to pursue or defend against litigation
in order to protect our patent rights.
We also rely on trade secret protection for our unpatented proprietary
technology. However, trade secrets are difficult to protect. While we enter into
proprietary information agreements with our employees and consultants, these
agreements may not successfully protect our trade secrets or other proprietary
information.
WE ARE A SMALL COMPANY RELATIVE TO OUR PRINCIPAL COMPETITORS AND OUR LIMITED
FINANCIAL AND RESEARCH RESOURCES MAY LIMIT OUR ABILITY TO DEVELOP AND MARKET NEW
PRODUCTS.
Many companies, both public and private, including well-known
pharmaceutical companies such as Amgen, Inc. Bayer AG, Eli Lilly and Co.,
Novartis, Bristol-Meyers Squibb Company, Pfizer, Inc., and Janssen and Shire,
are developing products to treat Alzheimer's disease and certain of the other
applications we are pursuing. Most of these companies have substantially greater
financial, research and development, manufacturing and marketing experience and
resources than we do. As a result, our competitors may be more successful than
us in developing their products and obtaining regulatory approvals. While we
believe, based on recent industry publications, that Neotrofin(TM) is more
advanced in the drug development process than most other drugs seeking to use
neurotrophic factors to treat Alzheimer's disease, we cannot be certain that
Neotrofin(TM) will be the first of these drugs to receive FDA approval, if it
receives approval at all. In addition, there are four drugs currently approved
for the treatment of Alzheimer's disease in the United States, all of which use
a different approach to the disease than Neotrofin(TM). If these treatments are
successful, or if other drugs using the neurotrophic factor approach are
approved before Neotrofin(TM), the market for our products could be reduced or
eliminated.
OUR LACK OF EXPERIENCE AT CONDUCTING CLINICAL TRIALS OURSELVES MAY DELAY THE
TRIALS AND INCREASE OUR COSTS.
We have begun to conduct, and intend to conduct in the future, some
clinical trials ourselves rather than hiring outside contractors. We believe
this conversion may reduce the costs associated with the trials and give us more
control over the trials. However, while some of our management has had
experience at conducting clinical trials, we have never done so as a company.
While we have not experienced significant delays or increased costs to
4
8
date due to this conversion, as we move forward with our first self-conducted
clinical trials, our lack of experience may delay the trials and increase our
costs. We think it is prudent to expect setbacks as we make this transition.
OUR MANAGEMENT HAS LIMITED MANUFACTURING AND MARKETING EXPERIENCE AND MAY BE
UNABLE TO MANAGE OUR GROWTH OR MANUFACTURE AND MARKET OUR PRODUCTS SUCCESSFULLY.
To date, we have engaged exclusively in the development of
pharmaceutical technology and products. In order to commercially exploit our
products and achieve our business goals, assuming we receive FDA approval of one
or more of our potential products, we will have to establish strategic
relationships with other companies that have manufacturing and marketing
capabilities or develop these capabilities ourselves. Our management has
substantial experience in pharmaceutical company operations, but has limited
experience in manufacturing or procuring products in commercial quantities or in
marketing pharmaceutical products. Our management has only limited experience in
negotiating, establishing and maintaining strategic relationships, conducting
clinical trials and other later-stage phases of the regulatory approval process.
If we receive FDA approval of any of our potential products, and if we
are not able to establish satisfactory relationships with other companies that
can meet our resulting manufacturing needs, we may decide to establish a
commercial-scale manufacturing facility for our products. The establishment of
such a facility will require substantial additional funds and personnel, and we
will need to comply with extensive regulations applicable to such a facility.
These requirements and the associated growth would strain our existing
management and operations. Our ability to manage such growth depends upon the
ability of our officers and key employees to:
- broaden our management team;
- develop additional expertise among existing management
personnel;
- attract, hire and retain skilled employees; and
- implement and improve our operational, management information
and financial control systems.
HOLDERS OF OUR CONVERTIBLE PREFERRED STOCK, DEBENTURES AND WARRANTS COULD ENGAGE
IN SHORT SELLING TO INCREASE THE NUMBER OF SHARES OF COMMON STOCK ISSUABLE UPON
CONVERSION OR EXERCISE OF THE SECURITIES AND DECREASE THE EXERCISE PRICE OF THE
WARRANTS. IF THIS OCCURS, THE MARKET PRICE OF OUR COMMON STOCK MAY DECLINE.
Short selling is a practice in which an investor borrows shares from a
stockholder to sell in the trading market, with an obligation to deliver the
same number of shares back to the lending stockholder at a future date. Short
sellers make a profit if the price of our common stock declines, allowing the
short sellers to sell the borrowed shares at a higher price than they have to
pay for shares delivered to the lending stockholder. Short selling increases the
number of shares of our common stock available for sale in the trading market,
putting downward pressure on the market price of our common stock.
We have issued a number of securities that may be converted into or
exercised for shares of our common stock based on a floating conversion or
exercise price related to the market price of our common stock. The holders of
these securities may benefit from the downward price pressures caused by short
selling due to the increased number of shares of common stock issuable upon
conversion of convertible securities at a lower conversion price, or the reduced
exercise price that must be paid to obtain shares of common stock upon exercise.
The holders of our Series C Preferred Stock have the right to convert
those shares into shares of our common stock at a rate that varies with the
market price of our common stock. The shares of our Series C Preferred Stock are
convertible into common stock at a conversion price equal to 100% of the average
of the lowest seven closing bid prices of our common stock in the previous 30
trading days, subject to a cap of $5.97. The holders of shares of Series A
Preferred Stock issued by our subsidiary, NeoGene Technologies, Inc., have
rights to exchange those shares for shares of our convertible preferred stock.
If we hold less than $5 million in cash and cash equivalents at the time of the
exchanges, these holders also have the right to exchange those shares into our
convertible debentures. If those exchange rights are exercised, the resulting
shares of our convertible preferred stock or debentures will generally be
convertible into common stock at a conversion price equal to 101% of the average
of the lowest ten closing bid prices of our common stock in the previous 30
trading days, subject to a cap of 120% of the market price of our common stock
at the time of the exchange. In addition, on April 17, 2001, we
5
9
entered into an agreement with the holders of NeoGene's Series A Preferred Stock
that commit these investors to purchase convertible debentures of
NeoTherapeutics. If issued, the convertible debentures will generally be
convertible into common stock at a conversion price equal to an initial
conversion price of 120% of the average per share market value of our common
stock over the five trading days preceding the date of issuance or, after 90
days from the date of issuance, the lesser of the initial conversion price or
101% of the average of the ten lowest closing bids of our common stock in the
previous 30 trading days from the date of conversion.
As a result of the terms of these securities, the number of shares of
common stock issuable upon conversion of the convertible preferred stock or
debentures will vary with the market price of our stock. The number of shares of
our common stock that are issuable upon conversion of any of these securities
increases as the price of our common stock decreases. Increased sales volume of
our common stock could put downward pressure on the market price of the shares.
This fact could encourage holders of the securities to sell short our common
stock prior to conversion of the securities, thereby potentially causing the
market price to decline and a greater number of shares to become issuable upon
conversion of the preferred stock or debentures. The holders of the securities
could then convert their securities and use the shares of common stock received
upon conversion to replace the shares sold short. The holders of the securities
could thereby profit by the decline in the market price of the common stock
caused by their short selling.
Similarly, the exercise price of our outstanding Class B Warrants, if we
deliver a redemption notice, is equal to the lesser of $33.75 per share (subject
to adjustment for stock splits, reverse splits and combinations) and 97% (or 95%
if the market price of our common stock is less than $5.00 per share) of the
closing bid price of our common stock on the trading day after the redemption
notice is delivered. This fact could give the holders of our Class B Warrants
incentive to sell short our common stock after receipt of a redemption notice,
which could cause the market price to decline. The holders of the Class B
Warrants could then exercise their Class B Warrants and use the shares of common
stock received upon exercise to replace the shares sold short and thereby profit
by the decline in the market price of the common stock caused by their short
selling. There are currently outstanding Class B Warrants exercisable for
3,413,600 shares of common stock.
Montrose Investments Ltd. and Strong River Investments, Inc. each hold
Class B Warrants to purchase 1,706,800 shares of our common stock and $2.5
million worth of NeoGene Series A Preferred Stock. Societe Generale holds $2.0
million worth of our Series C Preferred Stock. No other investors hold NeoGene
Preferred Stock, NeoTherapeutics Preferred Stock or Class B Warrants. In
addition, Montrose Investments Ltd. and Strong River Investments, Inc. are the
investors under our April 17, 2001 agreement for the purchase of convertible
debentures. These facts give these three investors greater influence over the
market price of our stock, however, each of these investors make independent
investment decisions, and each has agreed to vote any and all shares of our
common stock that they own as recommended by our board of directors in any
meeting of our stockholders.
THE TRADING PRICE OF OUR COMMON STOCK AND THE TERMS OF OUR CONVERTIBLE
SECURITIES AND WARRANTS MUST COMPLY WITH THE LISTING REQUIREMENTS OF THE NASDAQ
NATIONAL MARKET OR WE COULD BE DELISTED AND THE LIQUIDITY OF OUR COMMON STOCK
WOULD DECLINE.
Our common stock is listed on the Nasdaq National Market. To remain
listed on this market, we must meet Nasdaq's listing maintenance standards and
abide by Nasdaq's rules governing listed companies. If the price of our common
stock falls below $1.00 per share for an extended period, or if we fail to meet
other Nasdaq standards, including minimum market capitalization and minimum
total assets, or violate Nasdaq rules, our common stock could be delisted from
the Nasdaq National Market.
Nasdaq has established rules regarding the issuance of "future priced
securities" or securities convertible into common stock based on a floating
conversion price, so that the number of shares of common stock issuable upon
conversion of the securities is not known when the securities are sold. These
rules may apply to our Series C Preferred Stock, the preferred stock or
debentures we may issue in exchange for NeoGene preferred stock or the
convertible debentures we may issue pursuant to the April 17, 2001 agreement,
because the number of shares of our common stock issuable upon conversion of
these securities is based upon a future price of our common stock. Nasdaq's
concerns regarding these securities include the potential dilution to our
existing stockholders if the price of our common stock goes down causing a large
number of shares to be issued upon conversion of the securities, and the
corresponding potential for excessive return on investment for the purchaser of
the convertible securities. In
6
10
addition, since the holders of future priced securities may benefit from a
decrease in the market price of our common stock, those holders may have greater
incentive to engage in manipulative practices. In light of these concerns,
Nasdaq has indicated that the following rules may be implicated by future priced
securities:
Stockholders must approve significant issuances of listed securities at
a discount to market or book value. Nasdaq rules prohibit an issuer of listed
securities from issuing 20% or more of its outstanding capital stock at less
than the greater of book value or the then current market value without
obtaining prior stockholder consent. We did not obtain stockholder consent prior
to issuing the NeoGene preferred stock and granting the exchange right to the
holders of the NeoGene preferred stock or prior to signing the April 17, 2001
agreement. Prior to obtaining stockholder approval, the securities issued in
these transactions by their terms could not be converted into 20% or more of the
number of shares of our common stock outstanding at the time the securities are
issued. We obtained this approval at our Annual Meeting of Stockholders held on
June 11, 2001.
Public interest concerns. Nasdaq may terminate the listing of a security
if necessary to prevent fraudulent and manipulative acts and practices or to
protect investors and the public interest. With respect to future priced
securities, Nasdaq has indicated that it may delist a security if the returns
with respect to the future priced security become excessive compared to the
returns being earned by public investors in the issuer's securities.
Furthermore, some requirements for continued listing, such as the $1.00
minimum bid price requirement, are outside of our control. Accordingly, there is
a risk that Nasdaq may delist our common stock.
If our common stock is delisted, we likely would seek to list our common
stock on the Nasdaq SmallCap Market or for quotation on the American Stock
Exchange or a regional stock exchange. However, listing or quotation on such
market or exchange could reduce the market liquidity for our common stock. If
our common stock were not listed or quoted on another market or exchange,
trading of our common stock would be conducted in the over-the-counter market on
an electronic bulletin board established for unlisted securities or in what are
commonly referred to as the "pink sheets." As a result, an investor would find
it more difficult to dispose of, or to obtain accurate quotations for the price
of, our common stock. In addition, delisting from the Nasdaq National Market and
failure to obtain listing or quotation on such other market or exchange would
subject our common stock to so-called "penny stock" rules. These rules impose
additional sales practice and market-making requirements on broker-dealers who
sell and/or make a market in such securities. Consequently, if our common stock
is delisted from the Nasdaq National Market and we fail to obtain listing or
quotation on another market or exchange, broker-dealers may be less willing or
able to sell and/or make a market in our common stock and purchasers of our
common stock may have more difficulty selling such common stock in the secondary
market. In either case, the market liquidity of our common stock would decline.
THERE ARE A SUBSTANTIAL NUMBER OF SHARES OF OUR COMMON STOCK ELIGIBLE FOR FUTURE
SALE IN THE PUBLIC MARKET. THE SALE OF THESE SHARES COULD CAUSE THE MARKET PRICE
OF OUR COMMON STOCK TO FALL. ANY FUTURE EQUITY ISSUANCES BY US MAY HAVE DILUTIVE
AND OTHER EFFECTS ON OUR EXISTING STOCKHOLDERS.
There were 20,777,181 shares of our common stock outstanding as of June
22, 2001. In addition, security holders held options and warrants as of June 22,
2001 which, if exercised, would obligate us to issue up to an additional
11,662,018 shares of common stock as of June 22, of which 5,165,385 shares are
subject to options or warrants which are currently exercisable at the sole
election of the holder. Many of these shares, if issued, would likely be issued
at a discount to the prevailing market price. A substantial number of those
shares, when we issue them upon exercise, will be available for immediate resale
in the public market. In addition, we have the ability to sell up to
approximately $27 million of our common stock pursuant to a shelf registration
that will be eligible for immediate resale in the market. Furthermore, these
numbers do not include the number of shares of common stock that may become
issuable upon conversion of our Series C Preferred Stock or the securities that
we may be required to issue in exchange for shares of NeoGene preferred stock.
While this number of shares cannot be accurately determined at this time,
assuming an average conversion price of $5.00 per share and payment of all
dividends in shares, up to 1,790,000 shares could be issuable and available for
resale upon conversion of these securities. The market price of our common stock
could fall as a result of such resales, due to the increased number of shares
available for sale in the market. If all 13,452,018 shares were issued without
any increase in our market capitalization, the market price per share of our
common stock may be reduced by approximately 40%.
7
11
We have financed our operations, and we expect to continue to finance
our operations, by issuing and selling equity securities. Any issuances by us of
equity securities may be at or below the prevailing market price of our common
stock and may have a dilutive impact on our other stockholders. These issuances
would also cause our net income or loss per share to decrease in future periods.
As a result, the market price of our common stock could drop.
WE MAY BE SUBJECT TO PRODUCT LIABILITY CLAIMS, AND MAY NOT HAVE SUFFICIENT
PRODUCT LIABILITY INSURANCE TO COVER ANY CLAIMS, WHICH MAY EXPOSE US TO
SUBSTANTIAL LIABILITIES.
We may be exposed to product liability claims from patients who
participate in our clinical trials, or, if we are able to obtain FDA approval
for one or more of our potential products, from consumers of our products.
Although we currently carry product liability insurance in the amount of $5
million per occurrence, it is possible that the amounts of this coverage will be
insufficient to protect us from future claims. Further, we cannot be certain
that we will be able to obtain or maintain additional insurance on acceptable
terms for our clinical and commercial activities or that such additional
insurance would be sufficient to cover any potential product liability claim or
recall. Failure to maintain sufficient insurance coverage could have a material
adverse effect on our business and results of operations if claims are made that
exceed our coverage.
THE USE OF HAZARDOUS MATERIALS IN OUR RESEARCH AND DEVELOPMENT EFFORTS IMPOSES
CERTAIN COMPLIANCE COSTS ON US AND MAY SUBJECT US TO LIABILITY FOR CLAIMS
ARISING FROM THE USE OR MISUSE OF THESE MATERIALS.
Our research and development efforts involve the use of hazardous
materials, including biological materials, chemicals and radioactive materials.
We are subject to federal, state and local laws and regulations governing the
storage, use and disposal of these materials and some waste products. We believe
that our safety procedures for handling and disposing of these materials comply
with the standards prescribed by federal, state and local regulations. However,
we cannot completely eliminate the risk of accidental contamination or injury
from these materials. If there was an accident, we could be held liable for any
damages that result, which could exceed our resources. Currently the costs of
complying with federal, state and local regulations are not significant, and
consist primarily of waste disposal expenses. We may incur substantially
increased costs to comply with regulations, particularly environmental
regulations if we develop our own commercial manufacturing facility.
THE MARKET PRICE AND VOLUME OF OUR COMMON STOCK FLUCTUATE SIGNIFICANTLY AND
COULD RESULT IN SUBSTANTIAL LOSSES FOR INDIVIDUAL INVESTORS.
The stock market from time to time experiences significant price and
volume fluctuations that are unrelated to the operating performance of
particular companies. These broad market fluctuations may cause the market price
of our common stock to drop. In addition, the market price of our common stock
is highly volatile. Factors that may cause the market price of our common stock
to drop include fluctuations in our results of operations, timing and
announcements of our technological innovations or new products or those of our
competitors, FDA and foreign regulatory actions, developments with respect to
patents and proprietary rights, public concern as to the safety of products
developed by us or others, changes in health care policy in the United States
and in foreign countries, changes in stock market analyst recommendations
regarding our common stock, the pharmaceutical industry generally and general
market conditions. In addition, the market price of our common stock may drop if
our results of operations fail to meet the expectations of stock market analysts
and investors. During the last year, the price of our common stock has ranged
between $13.50 and $2.22, and the daily trading volume has been as high as
2,006,000 shares and as low as 10,600 shares, with a recent average of
approximately 112,000 shares.
OUR DIRECTORS AND EXECUTIVE OFFICERS OWN A SUBSTANTIAL PERCENTAGE OF OUR COMMON
STOCK. THEIR OWNERSHIP COULD ALLOW THEM TO EXERCISE SIGNIFICANT CONTROL OVER
CORPORATE DECISIONS AND TO IMPLEMENT CORPORATE ACTS THAT ARE NOT IN THE BEST
INTERESTS OF OUR STOCKHOLDERS AS A GROUP.
Our directors and executive officers beneficially own approximately
11.6% of our outstanding common stock as of June 21, 2001. In addition, several
of our stockholders, including Montrose Investments Ltd. and Strong River
Investments, Inc. and Societe Generale have agreed that they will vote any and
all shares of our common stock that they own as recommended by our board of
directors in any meeting of our stockholders. As of June 21, 2001, these
stockholders collectively held 1,649,157 shares of our common stock, or
approximately 8.0%, and held warrants and convertible securities which could
result in up to 6,823,146 additional shares, for a total of 8,092,303 shares or
29.8% of the total number outstanding if all of those securities were converted
or exercised, assuming a conversion price of $4.00 per share for
8
12
all floating price securities. Of the additional shares, only 1,780,000, or
approximately 7.9%, could be issued at the option of the holder within 60 days
of June 21, 2001. As a result of these holdings, our directors and executive
officers, if they acted together, could exert substantial influence over matters
requiring approval by our stockholders. These matters would include the election
of directors and the approval of mergers or other business combination
transactions. This concentration of ownership and voting power may discourage or
prevent someone from acquiring our business.
CERTAIN CHARTER AND BYLAWS PROVISIONS AND STOCKHOLDER RIGHTS PLAN MAY MAKE IT
MORE DIFFICULT FOR SOMEONE TO ACQUIRE CONTROL OF US OR REPLACE CURRENT
MANAGEMENT.
Certain provisions of our Certificate of Incorporation and Bylaws may
make it more difficult for someone to acquire control of us or replace our
current management. These provisions may make it more difficult for stockholders
to take certain corporate actions and could delay or discourage prevent someone
from acquiring our business or replacing our current management, even if doing
so would benefit our stockholders. These provisions could limit the price that
certain investors might be willing to pay for shares of our common stock.
On December 13, 2000, we adopted a Stockholder Rights Plan pursuant to
which we have distributed rights to purchase units of our capital Series B
Junior Participating Preferred Stock. The rights become exercisable upon the
earlier of ten days after a person or group of affiliated or associated persons
has acquired 20% or more of the outstanding shares of our common stock or ten
days after a tender offer has commenced that would result in a person or group
beneficially owning 20% or more of our outstanding common stock. These rights
could delay or discourage someone from acquiring our business, even if doing so
would benefit our stockholders.
FORWARD-LOOKING STATEMENTS
This prospectus and the documents incorporated by reference into this
prospectus contain forward-looking statements that are based on current
expectations, estimates and projections about our industry, management's
beliefs, and assumptions made by management. Words such as "anticipates,"
"expects," "intends," "plans," "believes," "seeks," "estimates," and variations
of such words and similar expressions are intended to identify such
forward-looking statements. These statements are not guarantees of future
performance and are subject to certain risks, uncertainties and assumptions that
are difficult to predict; therefore, actual results may differ materially from
those expressed or forecasted in any forward-looking statements. The risks and
uncertainties include those noted in "Risk Factors" above and in the documents
incorporated by reference.
We undertake no obligation to update publicly any forward-looking
statements, whether as a result of new information, future events or otherwise,
except to the extent that we are required to do so by law. We also may make
additional disclosures in our Annual Report on Form 10-K, Quarterly Reports on
Form 10-Q and Current Reports on Form 8-K that we may file from time to time
with the Securities and Exchange Commission. Please also note that we provide a
cautionary discussion of risks and uncertainties under the section entitled
"Risk Factors" in our Annual Report on Form 10-K. These are factors that we
think could cause our actual results to differ materially from expected results.
Other factors besides those listed here could also adversely affect us. This
discussion is provided as permitted by the Private Securities Litigation Reform
Act of 1995.
ISSUANCE OF COMMON STOCK TO THE SELLING STOCKHOLDERS
On December 18, 2000, we entered into a securities purchase agreement
with our subsidiary, NeoGene Technologies, Inc., and Societe Generale, a bank
organized under the laws of France, for the issuance and sale of preferred stock
and warrants for aggregate consideration of $2,000,025. Pursuant to the
securities purchase agreement, NeoGene issued and sold to Societe Generale a
total of 44,445 shares of its Series B Convertible Preferred Stock, no par value
per share, at a purchase price of $45 per share, and issued a five-year warrant
to purchase a total of 9,387 shares of NeoGene common stock, no par value per
share, at an exercise price of $45 per share. The NeoGene Series B Convertible
Preferred Stock is convertible into shares of NeoGene common stock on a
one-to-one basis, subject to certain antidilution adjustments, and automatically
converts upon the earlier to occur of December 18, 2005 or the closing of a
public offering of NeoGene common stock meeting certain criteria.
9
13
In addition, we issued to Societe Generale a five-year warrant to
purchase an aggregate of 30,000 shares of our common stock, par value $.001 per
share, at an exercise price of $6.10 per share. We also granted an exchange
right to Societe Generale which will allow them to exchange their shares of
NeoGene Series B Convertible Preferred Stock for our preferred stock.
Societe Generale has exercised its right to exchange all of the NeoGene
Series B Convertible Preferred shares held by them for 200 shares of our 7%
Series C Preferred Stock, $.001 par value per share. The 7% Series C Preferred
Stock is convertible into shares of our common stock at a conversion price equal
to the lesser of (i) $5.97 and (ii) 100% of the average of the lowest seven
closing bid prices of our common stock, as reported by The Nasdaq Stock Market,
during the thirty trading days immediately preceding the conversion.
Pursuant to a registration rights agreement we entered into with Societe
Generale, we have filed a registration statement, of which this prospectus forms
a part, in order to permit the selling stockholder to resell to the public the
shares of common stock that they acquire upon any exercise of the warrants or
upon conversion of the convertible preferred stock, assuming that they exercise
their exchange right. The number of shares that we have registered is based upon
the maximum number of shares issuable upon any exercise of the warrants and an
estimate of the number of shares issuable upon conversion or exercise of the
preferred stock.
Societe Generale has agreed that they will vote any and all shares of
our common stock that they own as recommended by our board of directors in any
meeting of our stockholders.
USE OF PROCEEDS
The proceeds from the sale of the common stock will belong to the
selling stockholder. We will not receive any proceeds from such sales.
SELLING STOCKHOLDERS
The following table sets forth information regarding beneficial
ownership of our common stock by the selling stockholder as of June 13, 2001.
The holder of the convertible preferred stock and warrants is prohibited from
using them to acquire shares of our common stock to the extent that such
acquisition would result in the holder, together with any affiliate of the
holder to have beneficial ownership levels of 4.9% of our common stock following
such acquisition.
Since the number of shares of our common stock that will be issuable
upon conversion of the convertible preferred stock is based upon fluctuations of
the market price of our common stock, prior to a conversion of these securities
the actual number of shares of our common stock that will be issuable and
beneficially owned upon conversion of such securities cannot be determined.
Because of this fluctuating characteristic, we have agreed to register a number
of shares of our common stock that exceeds the number of our shares of common
stock currently beneficially owned by the holder of the securities. The number
of shares of our common stock listed in the table below as being beneficially
owned by the selling stockholder includes the shares of our common stock that
are issuable to it, subject to the 4.9% limitation, upon conversion of our 7%
Series C Preferred Stock, assuming the exercise of the warrants owned by it.
However, the 4.9% limitation would not prevent the selling stockholder from
acquiring and selling in excess of 4.9% of the shares of our common stock
through a series of acquisitions and sales under the convertible preferred stock
or warrants while never beneficially owning more than 4.9% at one time.
The selling stockholder may sell up to 1,404,046 shares of our common
stock pursuant to this prospectus. The selling stockholder has not had any
material relationship with us or any of our affiliates or predecessors within
the past three years.
Shares of Common
Number of Stock Beneficially
Shares of Owned
Common Stock Number of Following the
Beneficially Shares of Offering(3)
Owned % of Common Stock --------------------
Name Before Offering Class Offered Hereby Number % of Class
---- --------------- ----- -------------- ------- ----------
10
14
Societe Generale 538,906(1) 2.5% 1,404,046(2) 0 0
-----------------
* Less than 1%.
(1) Includes 30,000 shares issuable upon exercise of the warrants and
508,906 shares issuable upon conversion of convertible preferred stock
within 60 days of June 28, 2001, assuming a conversion price of 3.93 per
share, the conversion price that would apply on June 28, 2001.
(2) Includes 30,000 shares issuable upon exercise of the warrants and
1,374,046 shares issuable upon conversion of convertible preferred
stock, which equals 200% of the number of shares that would be issuable
upon conversion of the preferred stock, assuming all dividends were paid
in stock and assuming a conversion price of 3.93 per share, the
conversion price that would apply on June 28, 2001.
(3) Assumes the sale by the selling stockholder of all of the shares of
common stock available for resale under this Prospectus.
PLAN OF DISTRIBUTION
The selling stockholder and any of its pledgees, assignees and
successors-in-interest may, from time to time, sell any or all of the shares of
common stock offered hereby on any stock exchange, market or trading facility on
which the shares are traded or in private transactions. These sales may be at
fixed or negotiated prices. The selling stockholders may use any one or more of
the following methods when selling shares:
- ordinary brokerage transactions and transactions in which the
broker-dealer solicits purchasers;
- block trades in which the broker-dealer will attempt to sell the
shares as agent but may position and resell a portion of the
block as principal to facilitate the transaction;
- purchases by a broker-dealer as principal and resale by the
broker-dealer for its account;
- an exchange distribution in accordance with the rules of the
applicable exchange;
- privately negotiated transactions;
- short sales;
- broker-dealers may agree with the selling stockholders to sell a
specified number of such shares at a stipulated price per share;
- a combination of any such methods of sale; and
- any other method permitted pursuant to applicable law.
The selling stockholder may also sell shares under Rule 144 under the
Securities Act, if available, rather than under this prospectus.
The selling stockholder may also engage in short sales against the box,
puts and calls and other transactions in our securities or derivatives of our
securities and may sell or deliver shares in connection with these trades. The
selling stockholder may pledge its shares to its brokers under the margin
provisions of customer agreements. If a selling stockholder defaults on a margin
loan, the broker may, from time to time, offer and sell the pledged shares. The
selling stockholder has advised us that they have not entered into any
agreements, understandings or arrangements with any underwriters or
broker-dealers regarding the sale of their shares other than ordinary course
brokerage arrangements, nor is there an underwriter or coordinating broker
acting in connection with the proposed sale of shares by the selling
stockholders.
Broker-dealers engaged by the selling stockholder may arrange for other
brokers-dealers to participate in sales. Broker-dealers may receive commissions
or discounts from the selling stockholders, or, if any broker-dealer acts as
agent for the purchaser of shares, from the purchaser, in amounts to be
negotiated. The selling stockholders do not expect these commissions and
discounts to exceed what is customary in the types of transactions involved.
11
15
The selling stockholder and any broker-dealers or agents that are
involved in selling the shares may be deemed to be "underwriters" within the
meaning of the Securities Act in connection with such sales. In such event, any
commissions received by such broker-dealers or agents and any profit on the
resale of the shares purchased by them may be deemed to be underwriting
commissions or discounts under the Securities Act.
We have agreed to pay all fees and expenses incident to the registration
of the shares, including fees and disbursements of counsel to the selling
stockholders. We have agreed to indemnify the selling stockholder against
certain losses, claims, damages and liabilities, including liabilities under the
Securities Act.
Upon notification to us by the selling stockholder that any material
arrangement has been entered into with a broker-dealer for the sale of shares
through a block trade, special offering, exchange distribution or secondary
distribution or a purchase by a broker or dealer, we will file a supplement to
this prospectus, if required, pursuant to Rule 424(b) under the Securities Act,
disclosing the following:
- the name of each such selling stockholder and of the
participating broker-dealer(s);
- the number of shares involved;
- the price at which such shares were sold;
- the commissions paid or discounts or concessions allowed to such
broker-dealer(s), where applicable;
- that such broker-dealer(s) did not conduct any investigation to
verify the information set out or incorporated by reference in
this prospectus; and
- other facts material to the transaction.
In addition, we will file a supplement to this prospectus when a selling
stockholder notifies us that a donee or pledgee intends to sell more than 500
shares of our common stock.
We have advised the selling stockholders that the anti-manipulation
provisions of Regulation M promulgated under the Securities Exchange Act of 1934
may apply to their sales of our shares offered by this prospectus.
VALIDITY OF COMMON STOCK
Latham & Watkins, Costa Mesa, California, will pass on the validity of
the issuance of the shares of common stock offered by this prospectus.
EXPERTS
The consolidated financial statements of the Company incorporated by
reference in this registration statement have been audited by Arthur Andersen
LLP, independent public accountants, as indicated in their report with respect
thereto, and are included herein in reliance upon the authority of said firm as
experts in giving said report. Reference is made to said report which states
that the Company is in the development stage, as described in Note 1 to the
consolidated financial statements.
LIMITATION ON LIABILITY AND DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION
FOR SECURITIES ACT LIABILITIES
Our bylaws provide for indemnification of our directors and officers to
the fullest extent permitted by law. Insofar as indemnification for liabilities
under the Securities Act of 1933 may be permitted to directors, officers or
controlling persons of the Company pursuant to the Company's Certificate of
Incorporation, as amended, bylaws and the Delaware General Corporation Law, the
Company has been informed that in the opinion of the Securities and Exchange
Commission such indemnification is against public policy as expressed in such
Act and is therefore unenforceable.
12
16
WHERE YOU CAN FIND MORE INFORMATION
We file annual, quarterly and special reports, proxy statements and
other information with the SEC. You may read and copy any document we file at
the SEC's public reference room at 450 Fifth Street, N.W., Washington, D.C.,
20549, and in the SEC's public reference rooms in New York, and Chicago. Please
call the SEC at 1-800-SEC-0330 for further information on the public reference
rooms. Our SEC filings are also available to the public at the SEC's web site at
http://www.sec.gov.
The SEC allows us to "incorporate by reference" the information we file
with them which means that we can disclose important information to you by
referring you to those documents instead of having to repeat the information in
this prospectus. The information incorporated by reference is considered to be
part of this prospectus, and later information that we file with the SEC will
automatically update and supersede this information. We incorporate by reference
the documents listed below and any future filings made with the SEC under
Sections 13(a), 13(c), 14, or 15(d) of the Securities Exchange Act of 1934 until
the selling stockholders sell all the shares:
- Our annual report on Form 10-K for the fiscal year ended
December 31, 2000, as amended by Form 10-K/A filed on April 25,
2001;
- Our quarterly report on Form 10-Q for the quarter ended March
31, 2001, filed on May 14, 2001;
- Our current reports on Form 8-K filed on February 16, 2001,
March 14, 2001 and May 21, 2001;
- Our definitive proxy statement filed on April 30, 2001, pursuant
to Section 14 of the Exchange Act in connection with our 2001
Annual Meeting of Stockholders; and
- The description of our common stock contained in the
Registration of Securities of Certain Successor Issuers filed
pursuant to Section 12(g) of the Exchange Act on Form 8-B on
June 27, 1997, including any amendment or reports filed for the
purpose of updating such description.
You can request a copy of these filings, at no cost, by writing or
telephoning us at the following address:
NeoTherapeutics, Inc.
Attn: Investor Relations
157 Technology Drive
Irvine, California 92618
(949) 788-6700
You should rely only on the information contained in this prospectus or
any supplement and in the documents incorporated by reference. We have not
authorized anyone else to provide you with different information. The selling
stockholders will not make an offer of these shares in any state where the offer
is not permitted. You should not assume that the information in this prospectus
or any supplement or in the documents incorporated by reference is accurate on
any date other than the date on the front of those documents.
This prospectus is part of a registration statement we filed with the
SEC (Registration No. ___ _________). That registration statement and the
exhibits filed along with the registration statement contain more information
about the shares sold by the selling stockholders. Because information about
contracts referred to in this prospectus is not always complete, you should read
the full contracts which are filed as exhibits to the registration statement.
You may read and copy the full registration statement and its exhibits at the
SEC's public reference rooms or their web site.
13
17
================================================================================
1,404,046 SHARES OF COMMON STOCK
NEOTHERAPEUTICS, INC.
PROSPECTUS
___________, 2001
NO DEALER, SALESPERSON OR OTHER INDIVIDUAL HAS BEEN AUTHORIZED TO GIVE ANY
INFORMATION OR TO MAKE ANY REPRESENTATIONS OTHER THAN CONTAINED OR INCORPORATED
BY REFERENCE IN THIS PROSPECTUS, AND IF GIVEN OR MADE, SUCH INFORMATION OR
REPRESENTATIONS MUST NOT BE RELIED UPON AS HAVING BEEN AUTHORIZED BY THE COMPANY
OR ANY UNDERWRITER. THIS PROSPECTUS DOES NOT CONSTITUTE AN OFFER OR SOLICITATION
BY ANYONE IN ANY JURISDICTION IN WHICH SUCH OFFER OR SOLICITATION IS NOT
AUTHORIZED OR IN WHICH THE PERSON MAKING SUCH OFFER IS NOT QUALIFIED TO DO SO OR
TO ANYONE TO WHOM IT IS UNLAWFUL TO MAKE SUCH OFFER OR SOLICITATION. NEITHER THE
DELIVERY OF THIS PROSPECTUS NOR ANY SALE MADE HEREUNDER SHALL, UNDER ANY
CIRCUMSTANCE, CREATE ANY IMPLICATION THAT THERE HAS NOT BEEN ANY CHANGE IN THE
AFFAIRS OF THE COMPANY SINCE THE DATE HEREOF.
================================================================================
18
PART II
INFORMATION NOT REQUIRED IN THE PROSPECTUS
Item 14. Other Expenses of Issuance and Distribution.
The following sets forth the estimated costs and expenses, all of which
shall be borne by the Company, in connection with the offering of the securities
pursuant to this Registration Statement:
Registration Fee $ 1,478.19
Accounting Fees and Expenses $ 6,000.00
Legal Fees and Expenses $10,000.00
Miscellaneous $ 5,000.00
----------
Total $22,478.19
==========
Item 15. Indemnification of Directors and Officers.
The bylaws of the Company provide for indemnification of the Company's
directors and officers to the fullest extent permitted by law. Insofar as
indemnification for liabilities under the Securities Act may be permitted to
directors, officers or controlling persons of the Company pursuant to the
Company's Certificate of Incorporation, bylaws and the Delaware General
Corporation Law (the "DGCL"), the Company has been informed that in the opinion
of the Commission such indemnification is against public policy as expressed in
such Act and is therefore unenforceable.
Section 102(b)(7) of the DGCL provides that a certificate of
incorporation may include a provision which eliminates or limits the personal
liability of a director to the corporation or its stockholders for monetary
damages for breach of fiduciary duty as a director, except for liability (i) for
any breach of the director's duty of loyalty to the company or its stockholders,
(ii) for acts or omissions not in good faith or which involve intentional
misconduct or a knowing violation of law, (iii) under Section 174 of the DGCL,
relating to prohibited dividends or distributions or the repurchase or
redemption of stock or (iv) for any transaction from which the director derives
an improper personal benefit. The Company's Certificate of Incorporation
includes such a provision. As a result of this provision, the Company and its
stockholders may be unable to obtain monetary damages from a director for breach
of his or her duty of care.
Item 16. Exhibits.
EXHIBITS: DESCRIPTION
--------- -----------
4.1 Securities Purchase Agreement dated as of December 18, 2000, by and
among Registrant, NeoGene Technologies, Inc. and Societe Generale.*
4.2 Certificate of Determination of NeoGene Technologies, Inc.*
4.3 Registration Rights Agreement dated as of December 18, 2000, by and
between NeoGene Technologies, Inc. and Societe Generale.*
4.4 Registration Rights Agreement dated as of December 18, 2000, by and
between Registrant and Societe Generale.*
4.5 Warrant issued by NeoGene Technologies, Inc. to Societe Generale, dated
as of December 18, 2000.*
4.6 Warrant issued by Registrant to Societe Generale, dated as of December
18, 2000.*
4.7 Certificate of Designations of the Series C Preferred Stock of the
Registrant.
5.1 Opinion of Latham & Watkins.
23.1 Consent of Latham & Watkins (included in Exhibit 5).
23.2 Consent of Arthur Andersen LLP.
24.1 Power of Attorney (included on this signature page to this Registration
Statement).
* Previously filed with the Commission as Exhibits to, and incorporated herein
by reference from, the Registrant's Current Report on Form 8-K filed with the
Commission on December 28, 2000.
II-1
19
Item 17. Undertakings.
(a) The undersigned registrant hereby undertakes:
(1) To file, during any period in which it offers or sells securities, a
post-effective amendment to this registration statement:
(iii) To include any material information with respect to the
plan of distribution not previously disclosed in the registration statement or
any material change to such information in the registration statement.
(2) That, for the purpose of determining any liability under the
Securities Act, each post-effective amendment shall be treated as a new
registration statement of the securities offered, and the offering of the
securities at that time to be deemed the initial bona fide offering.
(3) To remove from registration by means of a post-effective amendment
any of the securities being registered which remain unsold at the termination of
the offering.
(b) The undersigned registrant hereby undertakes that, for purposes of
determining any liability under the Securities Act of 1933, each filing of the
registrant's annual report pursuant to section 13(a) or section 15(d) of the
Securities Exchange Act of 1934 (and, where applicable, each filing of an
employee benefit plan's annual report pursuant to section 15(d) of the
Securities Exchange Act of 1934) that is incorporated by reference in the
registration statement shall be deemed to be a new registration statement
relating to the securities offered therein, and the offering of such securities
at that time shall be deemed to be the initial bona fide offering thereof.
(c) Insofar as indemnification for liabilities arising under the
Securities Act of 1933 may be permitted to directors, officers and controlling
persons of the registrant pursuant to the foregoing provisions, or otherwise,
the registrant has been advised that in the opinion of the Securities and
Exchange Commission such indemnification is against public policy as expressed
in the Act and is, therefore, unenforceable. In the event that a claim for
indemnification against such liabilities (other than the payment by the
registrant of expenses incurred or paid by a director, officer or controlling
person of the registrant in the successful defense of any action, suit or
proceeding) is asserted by such director, officer or controlling person in
connection with the securities being registered, the registrant will, unless in
the opinion of its counsel the matter has been settled by controlling precedent,
submit to a court of appropriate jurisdiction the question whether such
indemnification by it is against public policy as expressed in the Act and will
be governed by the final adjudication of such issue.
II-2
20
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the
Registrant certifies that it has reasonable grounds to believe that it meets all
of the requirements for filing on Form S-3 and has duly caused this Registration
Statement to be signed on its behalf by the undersigned, thereunto duly
authorized, in the City of Irvine, State of California, on June 29, 2001.
NEOTHERAPEUTICS, INC.
By: /s/ Samuel Gulko
------------------------------------
Samuel Gulko
Senior Vice President, Finance,
Chief Financial Officer, Secretary
and Treasurer
POWER OF ATTORNEY
We, the undersigned directors and officers of NeoTherapeutics, Inc., do
hereby constitute and appoint Alvin J. Glasky, Ph.D. and Samuel Gulko, or either
of them, our true and lawful attorneys-in-fact and agents, each with full power
to sign for us or any of us in our names and in any and all capacities, any and
all amendments (including post-effective amendments) to this Registration
Statement, or any related registration statement that is to be effective upon
filing pursuant to Rule 462(b) under the Securities Act of 1933, as amended, and
to file the same, with all exhibits thereto and other documents required in
connection therewith, and each of them with full power to do any and all acts
and things in our names and in any and all capacities, which such
attorneys-in-fact and agents, or either of them, may deem necessary or advisable
to enable NeoTherapeutics, Inc. to comply with the Securities Act of 1933, as
amended, and any rules, regulations, and requirements of the Securities and
Exchange Commission, in connection with this Registration Statement; and we
hereby do ratify and confirm all that the such attorneys-in-fact and agents, or
either of them, shall do or cause to be done by virtue thereof.
Pursuant to the requirements of the Securities Act of 1933, this
Registration Statement has been signed by the following persons in the
capacities and on the dates indicated.
SIGNATURE TITLE DATE
--------- ----- ----
/s/ Alvin J. Glasky Chief Executive Officer, Director June 29, 2001
--------------------------------- (principal executive officer)
Alvin J. Glasky, Ph.D.
/s/ Rajesh C. Shrotriya President, Chief Operating June 29, 2001
--------------------------------- Officer and Director
Rajesh C. Shrotriya, M.D.
/s/ Samuel Gulko Senior Vice President, Finance, June 29, 2001
--------------------------------- Chief Financial Officer,
Samuel Gulko Secretary, Treasurer and Director
(principal financial and
accounting officer)
/s/ Mark J. Glasky Director June 29, 2001
---------------------------------
Mark J. Glasky
/s/ Ann C. Kessler Director June 29, 2001
---------------------------------
Ann C. Kessler, Ph.D.
/s/ Armin M. Kessler Director June 29, 2001
---------------------------------
Armin M. Kessler
S-1
21
Director June 29, 2001
/s/ Eric L. Nelson
---------------------------------
Eric L. Nelson, Ph.D.
/s/ Carol O'Cleiracain Director June 29, 2001
---------------------------------
Carol O'Cleiracain, Ph.D.
/s/ Paul H. Silverman Director June 29, 2001
---------------------------------
Paul H. Silverman, Ph.D., D.Sc.
S-2
22
EXHIBIT INDEX
EXHIBITS: DESCRIPTION
--------- -----------
4.1 Securities Purchase Agreement dated as of December 18, 2000, by and
among Registrant, NeoGene Technologies, Inc. and Societe Generale.*
4.2 Certificate of Determination of NeoGene Technologies, Inc.*
4.3 Registration Rights Agreement dated as of December 18, 2000, by and
between NeoGene Technologies, Inc. and Societe Generale.*
4.4 Registration Rights Agreement dated as of December 18, 2000, by and
between Registrant and Societe Generale.*
4.5 Warrant issued by NeoGene Technologies, Inc. to Societe Generale,
dated as of December 18, 2000.*
4.6 Warrant issued by Registrant to Societe Generale, dated as of
December 18, 2000.*
4.7 Certificate of Designations of the Series C Preferred Stock of the
Registrant.
5.1 Opinion of Latham & Watkins.
23.1 Consent of Latham & Watkins (included in Exhibit 5).
23.2 Consent of Arthur Andersen LLP.
24.1 Power of Attorney (included on this signature page to this
Registration Statement).
* Previously filed with the Commission as Exhibits to, and incorporated herein
by reference from, the Registrant's Current Report on Form 8-K filed with the
Commission on December 28, 2000.